Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone look at the Nikola, youtube video last night? The ACT convention of BVEV and FCEV big rigs and trucks was last week. Anyway....
Nikola has built both types of trucks but the FCEV gets 500 miles to the tank and takes 20 minutes to refuel while the EV gets 300 miles to the tank and take 90 minutes to refuel....
Fumbler: You do realize that this article was published 16 months ago on January 10, 2022! Like really old news in the world of biotech!
How many votes do they need to pass #5?
I'm in - all in with a YES vote for #5.
By the way, this is not an A.I. generated video. Melon Toy is real. The name is unusual but she is a Covid victim.
Plug is down $1.28. Crazy…
We won't know, for certain, if the shareholders vote was negative but if Blackrock indeed owns 41 millions acres, surely they will vote positive?...
I’m rooting for you - $2.50!
Look Hoghead all I care about is the very immediate future - like today. Will we hit your sp goal of $2.50. Off to a good start...before the bell...
Hansen is part of the new triumvirate in biotech! And a major part of VIR Technology. VIR is an amazing company at the forefront of a new paradigm in medicine.
This is from LinkedIn:
"I received my Ph.D. in Microbiology from Oregon State University in 2001 under the mentorship of Dr. Dennis Hruby. After completing my degree, I took a post-doctoral position in the laboratory of Dr. Jay Nelson at OHSU’s Vaccine and Gene Therapy Institute, located on the campus of the Oregon National Primate Research Center. Working with Dr. Nelson and Dr. Louis Picker, I studied the Rhesus Cytomegalovirus (RhCMV) rhesus macaque model (RM) of infection, recombination, and immunobiology.
Currently I'm an Assistant Scientist working with Dr. Picker. Together we have pioneered the idea of “effector memory” -biased T cell (TEM) vaccines. Specifically, our research has focused on the development of recombinant CMV vectors, which generate and maintain TEM responses. Using the RhCMV and RM model we have demonstrated that RhCMV/SIV vectors can super-infect RhCMV+ RM, and upon super-infection elicit potent, persistent, and broadly targeted SIV-specific CD4+ and CD8+ T cell responses with a strong TEM bias. In the prophylactic vaccine setting, these responses have completely protected ~50% of vaccinated RM from progressive infection after limiting dose rectal challenge with the highly pathogenic SIVmac239 virus. These data indicate a novel pattern of protection consistent with very early stringent control, followed by progressive clearance of residual viral reservoirs, likely CD8+ TEM-mediated.
My current research is focused on designing and testing CMV vectors with genetically engineered restrictions in replication and dissemination/spread, with the goal to developing the safest CMV vectors with the greatest immunogenicity and protective capacity."
Picker, Hansen, Sacha - go to PubMed and look up their names.... They are together many times publishing....
Settle down now.
One last thing: "I can't wait for the first shared patent!"
Hansen's lab and the MAB - leronlimab!
IT CAN'T BE TRUE! Check out the bio on Dr. Scott Hansen:
Dr. Hansen’s research laboratory has been studying leronlimab since the Spring of 2021. In this time he has developed numerous flow cytometry biomarker assays to investigate how leronlimab/CCR5 modulates various immune cell phenotypes. Additionally, he developed an exploratory CCR5 receptor occupancy assay to evaluate leronlimab binding/loading after dosing. Dr. Hansen’s work has led to two research publications (one pending publication) that has already furthered CytoDyn’s understanding on the mechanism of action and potential applications of leronlimab in NASH and oncology.
SINCE 2021!!!
Oh No. It can't be true.
Check this out - a new member to CYDY's team - SCOTT HANSEN!
Can I say, "I'm cuckoo for cocoa Hansen's!"
https://www.cytodyn.com/our-team/management-team
scroll down
Even though this is about PLUG, FCEL could sooooooo easily do this too....
https://www.yahoo.com/finance/m/bf034fea-14a5-3162-aaa8-78347fd993a3/hydrogen-player-plug-power.html
Or maybe the fusion of Columbia Care into Cresco
Toyota hydrogen -conversion kit..
https://www.yahoo.com/autos/toyota-hydrogen-semi-conversion-kit-123900075.html
I think you are mistakenly using lol
Yes, I'm crazy. Just bought more. The price is just silly now with all its future prospects...nailed down.
I know that this is insane to say on this board but buying more of CYDY!
Give them time. Dare I say, Rome was not built in a day…
Never got on the 13D bandwagon and all the other nefarious schemes.
Just want Leronlimab to be in a genuine trial. That’s it.
I believe we have acknowledged that position at least a hundred times. If not, okay, here it is, I agree with you that this HAS BEEN a losing investment under the reins of a deceptive CEO and others and (DIS) honesty from a company that has taken my capital for illicit gains.
Now can we talk about NOW? NOW, today is a new day with different people who want to go forward with a measly sum of money and a non-saline antidote.
When he's part of the melon family.
I’m in agreement with you.
Do you think individual shareholders combined, if they all approve and vote for additional shares, is going to usurp the institutional investors?
Misiu: You should have talked to me. No, on second thought, I would have reiterated what Monroe, RockLeo, Biotech and others keep repeating. Lazarusleronlimab is the real deal.
What is the difference between efficacy and effectiveness with Leronlimab.
We have read that its efficacy is 81% - and that typically means under a controlled condition - like a test.
But what about it’s effectiveness? Effective is usually based on “real-world” conditions, and, thankfully, we have several persons who were succumbing to death when they were given RTT in the hopes of saving them.
Not only did they arise from their death bed but within days was discharged from the hospital.
Now that’s an effective antidote!
If I had an extra 100K, I would buy CYDY immediately based on what he SAID and DID!
CA: I’ve seen a lot of molecules over the last 15 years. I’ve also seen a lot of different clinical programs in which the same molecule is being used in different programs. To me, leronlimab has all the hallmarks of a winner.
I continually tell the team that we are really fortunate. It’s a gift that we have this molecule in our hands and that we can develop it, because we have something that we really believe works. The molecule is fantastic. There is a path here to value generation and to helping patients with this molecule. The future is exciting. We look forward to coming together with a strategic partner that can help CytoDyn get this molecule over the finish line.
LET ME REMIND EVERYONE - directly from the President:
"The FDA requested that CytoDyn address five discreet items. Three have been submitted to the agency, and the other two should be submitted shortly. The FDA will then have 30 days to review the information and will hopefully lift the hold."
"Once that is taken care of, we plan to go out and raise financing to fund operations. Once the financing has been stabilized, we will bring people onboard with relevant biotech experience and expertise that can support our development goals, which include starting a NASH trial and continuing to invest in and advance our long-acting CCR5 molecule. A corporate rebranding campaign will also be implemented to put some of these issues in the past while creating a new face for the company."
"We will bring people onboard..." Hansen??
Remember that cereal slogan:
I'm Cuckoo for Cocoa Puffs? I'm Cuckoo until Tuesday's Puff...
In your estimation, what do you think is happening to Plug? Everyday we see multi $ investment in Fuel Cells but the stocks that revolve in that sector are still being hammered...
AND - Sacha and Hansen authored published papers together!
Biotech Investor: Lovely paragraph. Finally, we can be excited without the dread of Nader yanking us down for the Nth time. I'm looking forward to Leronlimab's workhorse ethic. RISE UP dead men. Arise and come live in this world.
2 peer reviewed papers is not saline publishing. it's real. it's verifiable and it's about the one molecule that is nicknamed Lazarusleronlimab.
Back in the old days, as one would say, when country doctors were prevalent and medicine was in its infancy, the prime function of their care centered on OBSERVATION! Today, Leronlimab's efficacy has the ability to perform Lazarus feats of health. As an investor, I have witnessed and read of very sick people rising from their death bed, whether it be because of HIV, COVID and other CCR5 related illness. This is why I am here to tell all that Leronlimab is real and genuine.
I can say it enough. Leronlimab is the 500 lb. elephant with the most efficacy. That's why I am here. I don't care about all of the past officers in CYDY. I just want to talk about Leronlimab's efficacy and why so many investors have not sold.
Like MountainM, I am all in with Leronlimab and Misiu.
Most of the cannabis stocks are 98% down! You are not telling us anything new.
The shorts love this stock. Big licorice worms.